BridgeBio Pharma, Inc.
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(382,942) | $(538,303) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Noncash interest expense on deferred royalty obligations (1) | 123,500 | 86,460 |
| Stock-based compensation | 117,171 | 98,385 |
| Net loss from equity method investments | 32,030 | 51,579 |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | (7,098) | (11,062) |
| Amortization of debt discount and issuance costs | 5,670 | 4,515 |
| Depreciation and amortization | 3,308 | 3,999 |
| Noncash lease expense | 4,714 | 3,443 |
| Loss on extinguishment of debt | — | 21,155 |
| Noncash income from an equity method investment | — | (7,769) |
| Other noncash adjustments, net | 2,233 | (1,217) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (235,646) | (111,796) |
| Inventories | (35,641) | (23,356) |
| Prepaid expenses and other current assets | (26,872) | (17,527) |
| Other assets | (5,849) | 568 |
| Accounts payable | 51,993 | 9,084 |
| Accrued compensation and benefits | (9,049) | 3,212 |
| Accrued research and development liabilities | 13,583 | 347 |
| Operating lease liabilities | (5,494) | (4,757) |
| Deferred revenue | (6,558) | (9,480) |
| Other liabilities (2) | 48,397 | 53,030 |
| Net cash used in operating activities | (312,550) | (389,490) |
| Investing activities: | ||
| Purchases of marketable securities | (63,937) | (10,876) |
| Maturities of marketable securities | 76,500 | 8,000 |
| Proceeds from special cash dividends received from an investment in equity securities | — | 2,302 |
| Payment for intangible assets | — | (8,495) |
| Purchases of property and equipment | (802) | (1,064) |
| Net cash provided by (used in) investing activities | 11,761 | (10,133) |
| Financing activities: | ||
| Proceeds from issuance of 2033 Notes | 632,500 | — |
| Issuance costs and discounts associated with 2033 Notes | (13,227) | — |
| Proceeds from issuance of 2031 Notes | — | 575,000 |
| Issuance costs and discounts associated with 2031 Notes | — | (12,034) |
| Repayment of term loans | — | (459,000) |
| Proceeds from royalty obligation under Royalty Purchase Agreement (as described in Note 9) | — | 300,000 |
| Issuance costs associated with royalty obligation under Royalty Purchase Agreement | — | (3,010) |
| Repayments of deferred royalty obligations (3) | (62,507) | (6,896) |
| Proceeds from issuance of preferred stock | 933,900 | — |
| Issuance costs associated with preferred stock | (1,342) | — |
| Payment of preferred stock dividends | (2,694) | — |
| Repurchase of common stock | (252,502) | (48,276) |
| Proceeds from stock option exercises, net of repurchases | 33,712 | 14,523 |
| Proceeds from common stock issuances under ESPP | 9,728 | 6,414 |
| Repurchase of RSU shares to satisfy tax withholding | (13,431) | (6,796) |
| Transactions with noncontrolling interests | — | 1,550 |
| Net cash provided by financing activities | 1,264,137 | 361,475 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 963,348 | (38,148) |
| Cash, cash equivalents, and restricted cash at beginning of period | 572,140 | 683,244 |
| Cash, cash equivalents, and restricted cash at end of period | $1,535,488 | $645,096 |
(1)Including related party amounts of $13,878 and $5,560 for the period from January 1, 2026 to August 16, 2026 and for the nine months ended September 30, 2025, respectively (as described in Note 9).
(2)Including related party amounts ofnil and $1,647 for the period from January 1, 2026 to August 16, 2026 and for the nine months ended September 30, 2025, respectively (as described in Note 9).
(3)Including related party amounts of $(5,784) and $(665) for the period from January 1, 2026 to August 16, 2026 and for the nine months ended September 30, 2025, respectively (as described in Note 9).
\
Condensed Consolidated Statements of Cash Flows
(Continued)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for interest | $43,135 | $43,670 |
| Supplemental Disclosures of Noncash Investing and Financing Information: | ||
| Accretion of preferred stock | $9,920 | $— |
| Accrued cash dividends on preferred stock | $13,679 | $— |
| Accrual for repurchase of common stock | $4,997 | $— |
| Transfers to noncontrolling interests | $(8,765) | $(4,734) |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $1,533,363 | $642,951 |
| Restricted cash — Included in “Prepaid expenses and other current assets” | 550 | 126 |
| Restricted cash — Included in “Other assets” | 1,575 | 2,019 |
| Total cash, cash equivalents and restricted cash at end of periods shown on the condensed consolidated statements of cash flows | $1,535,488 | $645,096 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.